Clinical Trials for Hereditary Angioedema
Hereditary angioedema (HAE) is a rare genetic disorder that causes episodes of sudden swelling in the skin, gastrointestinal tract, and airway. HAE attacks can be painful, debilitating, and in the case of throat swelling, life-threatening. The condition is caused by a deficiency or dysfunction of C1 inhibitor protein, and it requires specialized treatment -- both for preventing attacks and for treating them when they occur.
Treatment for HAE has improved significantly over the past decade, but access to these medications is frequently blocked by insurance prior authorization and coverage denials. Clinical trials are developing new prophylactic and acute treatments that may offer improved protection with less frequent dosing.
The US Hereditary Angioedema Association estimates that HAE affects approximately 1 in 50,000 people, making it a rare but well-represented area of clinical research.
What Types of Trials Are Available?
Subcutaneous prophylaxis trials study new long-acting agents that could provide protection against HAE attacks with less frequent dosing than currently approved options. Some trials are studying agents that require only quarterly or biannual injection. Kallikrein and bradykinin pathway trials target the molecular mechanisms underlying HAE attacks -- including plasma kallikrein inhibitors, bradykinin B2 receptor antagonists, and factor XII inhibitors. Several approaches are in active trials. Gene therapy and RNA-based trials represent the newest frontier, with the goal of providing long-term or permanent correction of the underlying C1 inhibitor deficiency. Early-phase trials are underway. Pediatric HAE trials specifically study safety and efficacy in children and adolescents, a population with distinct needs.Search ClinicalTrials.gov for currently recruiting HAE trials.
Am I Eligible?
Common eligibility factors for HAE trials include:
- Confirmed HAE diagnosis (Type I or Type II, with documented C1 inhibitor deficiency or dysfunction)
- Attack frequency over a defined observation period
- Prior prophylactic or acute treatment history
- No current participation in other interventional trials
- Some trials require a specific age range or exclude people with recent serious infections
HAE is a rare disease, and trial sites are often at specialized centers with HAE expertise. Ask your allergist or immunologist whether they are involved in or aware of active trials.
Talk to your doctor before making any decisions about your treatment.
What If My Insurance Denied My Medication?
HAE medications -- including lanadelumab (Takhzyro), C1 inhibitor concentrates (Haegarda, Cinryze, Berinert), and icatibant (Firazyr) -- are among the most expensive specialty medications on the market, and prior authorization denials are common. Given the potentially life-threatening nature of HAE attacks, coverage delays are not just inconvenient -- they can be dangerous.
If your doctor has prescribed an HAE prophylactic or acute treatment and your insurer has denied it, appeal quickly and document the medical urgency. Work with your doctor to provide a clear picture of your attack history and the risks of inadequate prophylaxis.
Clinical trials may offer access to newer prophylactic agents -- some with less frequent dosing than currently approved medications.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Are clinical trials for hereditary angioedema free?
In most cases, yes. Trial sponsors (pharmaceutical companies, universities, or the NIH) cover the cost of the experimental treatment. You may still have costs for routine care — like doctor visits or standard tests — depending on your insurance. Always ask the trial coordinator what costs you might be responsible for before enrolling.
How do I find hereditary angioedema trials near me?
The best place to start is ClinicalTrials.gov, the official registry of all trials in the US. Search by condition name and filter by your location. Your specialist can also help identify trials at academic medical centers in your region.
Can I join a trial after being denied Takhzyro or Haegarda?
Yes, and in many cases a denial can actually make you a stronger candidate — trials often enroll patients who have not responded to or cannot access standard treatments. Talk to your doctor about whether your denial history makes you eligible for open trials studying Takhzyro or Haegarda or similar medications.